

Federico Monaco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4612540/publications.pdf>

Version: 2024-02-01

24
papers

278
citations

1040056

9
h-index

940533

16
g-index

25
all docs

25
docs citations

25
times ranked

572
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplantation, 2022, , .	2.4	1
2	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3120-3131.	1.6	29
3	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood, 2021, 137, 3027-3036.	1.4	40
4	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. Blood Cancer Journal, 2021, 11, 197.	6.2	5
5	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. Blood Cancer Journal, 2020, 10, 58.	6.2	9
6	Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms. Haematologica, 2019, 104, 1221-1229.	3.5	14
7	Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e321-e323.	0.4	0
8	Lenalidomide in Pretreated Patients with Diffuse Large Bâ€Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. Oncologist, 2019, 24, 1246-1252.	3.7	10
9	Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e271.	0.4	0
10	Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology. Dentistry Journal, 2018, 6, 42.	2.3	2
11	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the <i>Fondazione Italiana Linfomi</i>. Haematologica, 2018, 103, 1345-1350.	3.5	45
12	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. Thrombosis and Haemostasis, 2017, 117, 1615-1621.	3.4	27
13	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. Journal of Hematology and Oncology, 2016, 9, 38.	17.0	34
14	Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2214-2219.	2.0	13
15	A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 1664-1670.	2.0	15
16	PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). Thrombosis Research, 2016, 140, S177.	1.7	16
17	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. Leukemia and Lymphoma, 2016, 57, 2370-2374.	1.3	5
18	Prognostic Impact of p190 and p210 Co-Expression in Early Molecular Response in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosin Kinase Inibitors. Blood, 2016, 128, 5446-5446.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. <i>Blood</i> , 2015, 126, 3937-3937.	1.4	1
20	Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 3934-3934.	1.4	1
21	Successful HLA haploidentical myeloablative stem cell transplantation for aggressive hepatosplenic alpha/beta (Î±Î²) T-cell lymphoma. <i>Leukemia Research Reports</i> , 2014, 3, 90-93.	0.4	2
22	Prognostic Impact of p190 and p210 Co-Expression at Diagnosis in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib. <i>Blood</i> , 2014, 124, 5528-5528.	1.4	4
23	Monoclonal Gammopathy After Allogeneic Hematopoietic Stem Cell Transplant As a Marker For GvHD Onset. <i>Blood</i> , 2013, 122, 5484-5484.	1.4	0
24	SURVIVAL OF MYELOMA PATIENTS RECEIVING BISPHOSPHONATES IN A "REAL LIFE" EXPERIENCE: POTENTIAL IMPACT ON RISK OF OSTEONECROSIS OF THE JAW (ONJ). <i>Qeios</i> , 0, , .	0.0	0